Skip to main content
Download PDF

Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis

BMC Pulmonary Medicine volume 22, Article number: 316 (2022) Cite this article

Abstract

Background

NLR is a systemic inflammatory marker that have been associated with overall survival in patients with some rapidly progressive disease. There are few data about the diagnostic and predictive value of NLR in autoimmune diseases, and it has not been described in anti-MDA5 positive DM. We try to correlate neutrophil-to-lymphocyte ratio (NLR) with fatality from dermatomyositis in anti-MDA5 positive patients.

Method

A retrospective study in which 195 patients were enrolled was conducted. Clinical and laboratory information was collated and ratios of neutrophil to lymphocyte counts (NLR) calculated. The primary end point was all-cause death.

Result

Of the 195 patients studied, all had interstitial lung disease, including 140 survivors and 55 non-survivors. An optimal NLR cut-off value of 4.86 for mortality prediction was identified. The NLR of non-survivors was significantly higher than that of survivors (p < 0.001). Plasma levels of lactate dehydrogenase (LDH) and C-reactive protein were significantly increased when NLR was greater than 4.86. Results of multivariate analysis established that NLR > 4.86 was an independent predictor of mortality (HR: 2.52; 95%CI: 1.33–4.78; p = 0.005). Abstinence from smoking (HR: 2.66; 95%CI: 1.33–4.78; p = 0.003), emergence of rapidly progressive interstitial lung disease (RPILD; HR: 4.38; 95%CI: 2.37–8.08; p < 0.001), low plasma LDH (HR: 3.82; 95%CI: 2.06–7.11; p < 0.001) and presentation with dyspnea (HR: 2.17; 95%CI: 1.22–3.86; p = 0.009) were all protective factors predictive of survival.

Conclusion

NLR is a cost-effective and widely accessible biomarker with utility for risk stratification in patients with anti-MDA5 + dermatomyositis.

Peer Review reports

Introduction

Anti-MDA5 + dermatomyositis (DM) is an idiopathic inflammatory myopathy (IIM) which commonly presents with skin manifestations and progresses to pulmonary involvement. The involvement of muscle tissue is relatively rare. Patients testing positive for anti-MDA5 account for 13–30% of all IIM [1]. During inflammatory activation, patients are prone to rapidly progressive pulmonary interstitial lesions which result in high mortality. Vascular inflammation is a dominant part of inflammatory activation and peripheral blood neutrophils and lymphocytes participate in the process [2]. The ratio of neutrophil to lymphocyte counts (NLR) is an indicator of systemic inflammation which is easier to obtain than other inflammatory indicators, such as plasma lactate dehydrogenase (LDH) or ferritin. Levels of LDH [3] and ferritin [4, 5] are well-established as good prognostic indicators, allowing correlations to be made between the severity of the disease and survival time. To date, little data regarding the diagnostic and predictive value of NLR in autoimmune diseases has been reported and any utility for anti-MDA5 + DM has not been evaluated. Therefore, the current study aimed to determine whether NLR has value for mortality prediction in cases of anti-MDA5 + DM.

Methods

Patient enrollment

Patients receiving treatment for anti-MDA5 + DM in West China Hospital, Sichuan, China between December 2015 and September 2021 were retrospectively recruited. The study was approved by the bioethics committee of West China Hospital (NO.246 in 2019). Anti-MDA5 + DM was diagnosed according to the guidelines published by the 239th European Neuro Muscular Center [6]. Interstitial lung disease (ILD) diagnosis relies on symptoms, signs and high-resolution CT (HRCT) [7]. Rapidly progressing ILD (RP-ILD) was defined according to the criteria proposed by Akira et al. [8] and HRCT score evaluated by 2 independent radiologists, according to the method of Ichikado et al. [9]. All patients were given unique ID numbers on enrollment. Some patients were regularly followed up in our hospital and patient survival status was confirmed from the electronic medical record. Other patients were not regularly followed up and families were contacted for survival information, including time and cause of death. Neutrophil and lymphocyte counts were recorded on the patient’s first admission. NLR was defined as absolute neutrophil count divided by absolute lymphocyte count. Plasma levels of creatine kinase (CK), LDH and C-reactive peptide (CRP) were recorded, along with other clinical symptoms. Titers of anti-MDA5 antibodies were analyzed by transfection (Shaanxi MY Biotech Co., Ltd.).

Statistical analysis

All data analysis was performed using R statistical programming package, version 4.1.3 (R Programming). Overall survival (OS) was calculated from first treatment to death (event) or to last follow-up (census). The Kolmogorov–Smirnov test was used to assess the normality and homogeneity of variance of all the data. Data are presented as mean ± standard deviation when normally distributed or median and interquartile range (IQR) for non-normally distributed continuous variables and numbers (percentages) for categorical variables. Univariate and multivariate COX regression analyses were performed to identify independent risk factors with an impact on OS. OS curves and comparisons were calculated by Kaplan–Meier survival curves and the log-rank test. The optimal truncation value of NLR affecting prognosis was determined by receiver operator characteristic (ROC) curve in R Programming. All statistical tests were two sided and a p < 0.05 considered statistically significant.

Results

A total of 234 anti-MDA5 + DM patients were identified during the period between December 2015 and September 2021. Of the total, 4 patients were excluded due to missing core data and 35 patients presented without ILD on first admission and were excluded on the grounds that patients without ILD had a better prognosis than those with ILD. After these exclusions, 195 patients remained and were enrolled. There were 31 patients who did not receive corticosteroids at baseline for whom NLR data were obtained: 164 patients received corticosteroids. Baseline patient characteristics are shown in Table 1. The median value for months of the observational period was 26.5 (95% CI: 21.2–29.3). The mean age of the cohort was 50.34 ± 10.56 years. Two thirds (68.21%) were female, and the majority (83.59%) had never smoked. The mean survival time of the NLR ≥ 4.86 group was 58.85 months and that of the NLR ≤ 4.86 group was 34.41 months, p < 0.001. Some patients had comorbidities, such as heart failure (8.72%), diabetes (8.72), fatty liver (20.00%) and hypertension (7.18%), although these comorbidities appeared to have little impact on prognosis. More than half of the patients had arthralgia (61.54%), Gottron sign (61.54%) or heliotrope sign (51,79%). Almost half had developed dyspnea by the first admission (42.05%). Skin ulcers were relatively rare (11.79%). The median survival time was 13.50 months (1.64–32.56 months). Levels of inflammatory biomarkers, such as LDH (p < 0.001), CRP (p < 0.001) and red blood cell distribution width (RDW) (p = 0.025), showed significant differences between survivors and non-survivors. Non-survivors had higher CK levels than survivors (80.00 IU/L vs 51.00 IU/L; p = 0.002). Median values for white blood cell and platelet counts were 5.59 × 109/L (4.06–7.44 × 109/L) and 195.22 ± 71.36 × 109/L, respectively. The median NLR value was 4.85 (3.41–7.07) with lower values in anti-MDA5 + survivors than in non-survivors (4.34 vs 6.19; p < 0.001). Changes in NLR were synchronized with those of other inflammatory markers, such as LDH (Fig. 1a) and CRP (Fig. 1b).

Table 1 Demographic and clinical characteristics of different groups of anti-MDA5 + patients with ILD
Full size table
Fig. 1
figure 1

Median and interquartile range of LDH (a) and CRP (b) related to NLR. Abbreviation: LDH: lactate dehydrogenase; CRP: C-reactive protein; NLR: neutrophils/lymphocyte ratio

Full size image

Univariate and multivariate analysis

Results of univariate analysis showed that NLR (p < 0.001), plasma LDH (p < 0.001), smoking (p < 0.009), RPILD (p < 0.001), dyspnea (p < 0.001) and HRCT score were associated with OS of MDA5 + DM patients (Table 2).

Table 2 Variables associated with death among patients with anti-MDA5 + DM from Univariable Cox Regression Analysis
Full size table

Factors identified by univariate analysis as being related to survival were subjected to multivariate COX regression analysis. Neutrophil count, platelet count, creatine kinase and white blood cell count were omitted from data presented from Cox univariate regression analysis because p ≥ 0.05. The optical truncation value of NLR affecting the prognosis was found to be 4.86 by R statistical analysis (Additional file 1: Fig. S1). The Youden index was 0.37, the sensitivity was 0.74, the specificity was 0.62 and the positive and negative predictive values were 0.43 and 0.859. Kaplan–Meier curves showed that patients with a lower NLR (< 4.86) at baseline showed significantly higher OS compared with those with a higher NLR (≥ 4.86) at baseline (p < 0.001; Fig. 2).

Fig. 2
figure 2

Survival curve of anti-MDA5 + DM patients with ILD based on initial NLR. The survival rate was calculated by the Kaplan-meier test and compared using the log-rank test. Abbreviation: NLR: neutrophils/lymphocyte ratio

Full size image

Patients with a history of smoking had a higher risk of death than non-smokers (HR: 2.66; 95%CI: 1.33–4.78; p = 0.003). The prognosis of patients with RPILD was poorer than patients without RPILD (HR: 4.38; 95%CI: 2.37–8.08; p < 0.001). Levels of plasma LDH (HR: 3.82; 95%CI: 2.06–7.11; p < 0.001) and dyspnea (HR: 2.17; 95%CI: 1.22–3.86; p = 0.009) were predictive of survival. However, HRCT score was not a prognostic indicator for anti-MDA5 + DM patients (Table 3). A forest plot for subgroup analyses of overall survival is presented in Fig. 3.

Table 3 Variables associated with death among patients with anti-MDA5 + DM from Multivariable Cox Regression Analysis
Full size table
Fig. 3
figure 3

Forest plot of the multivariable cox analysis of the prognostic factors for patients with ILD in anti-MDA5 + DM of the discovery cohort. The indicates the weight of the variable in the multivariable cox analysis; higher number indicates greater weight; variables with P < 0.05 in the univariate analysis were included in the multivariable analysis. Abbreviation: LDH: lactate dehydrogenase; RPILD: rapidly progressive interstitial lung disease; HRCT: high-resolution CT; NLR: neutrophils/lymphocyte ratio

Full size image

Discussion

DM is a heterogeneous autoimmune disease with the anti-MDA5 + form exhibiting a characteristic rash and interstitial lung disease (ILD). The involvement of muscle tissue is rare, so that serum CK levels are usually normal. However, many patients develop rapidly progressive acute pulmonary failure, accounting for high mortality rates [10].

Neutrophils and lymphocytes play important roles in systemic autoimmune diseases with numbers and functions changing during disease progression. A component of the routine blood cell examination (RBC), NLR values have attracted increased attention in recent years for their utility in inflammatory and autoimmune disease. Previous work has indicated that NLR reflects disease activity in rheumatoid arthritis (RA) [11] and Bechet disease (BD) [12, 13], is a predictive marker for psoriatic arthritis (PsA) [14] and relates to the occurrence of lupus nephritis in systemic lupus erythematosus (SLE) [15, 16]. However, to the best of our knowledge, the relationship between NLR and MDA5 + DM has not been previously studied. Multiple indicators have been correlated with the prognosis of anti-MDA5 + DM, such as anti-MDA5 tilter [17], ferritin [4, 5, 17, 18], KL-6 [19] and the proportion of CD4 + CXCR4 + T cells [20]. The current study revealed elevated NLR to be an independent predictor for poor survival in anti-MDA5 + DM patients, in addition to LDH, CRP and other inflammatory indicators.

Knowledge regarding the pathogenic mechanisms of DM remains limited but it seems to disproportionately affect genetically susceptible populations and is triggered by infectious agents (viruses, picornaviruses, flaviviruses) [2]. Neutrophils and lymphocytes produce a variety of cytokines and participate in DM pathogenesis. Vasculopathy is a well-established feature of MDA 5 + DM [21, 22]. Oxidative stress is involved in the pathophysiology of vascular inflammation in DM [23, 24]. Oxidative stress is associated with excessive inflammatory activity and NLR is a non-specific indicator of oxidative stress, reflecting the state of the body’s immune system [25, 26]. Antigen-stimulated responses in autoimmune diseases include production of reactive oxygen species and the resulting oxidative stress has an impact on disease progression, response to therapy and prognosis. NLR correlates with inflammatory factors, such as CRP, LDH and ferritin, and interplay of multiple factors, including pro- and anti-inflammatory factors, may be responsible for measured NLRs. NLR is also related to other pathological conditions, such as cancer [27,28,29], osteoarthritis [30, 31] and myocardial infarctions [32, 33].

NLR measurements are relatively inexpensive and easily incorporated into routine clinical practice. The predictive properties of NLR allow it to serve as a prognostic marker to aid clinical decision-making at an early stage of anti-MDA5 + DM disease. Anti-MDA5 + DM has a high mortality rate due to the common development of rapidly progressive interstitial lung disease (RP-ILD) which is difficult to treat, especially in combination with infection [34,35,36]. Seasonal and geographical variations in anti-MDA5 + DM suggest that infections, especially viruses, may be a predisposing factor, perhaps due to the induction of a cytokine storm [37, 38]. Viral RNA activates MDA5 in infected cells, leading to the production of type I interferon (IFN-I) and cytokines [38]. Increased neutrophils during bacterial infection and decreased lymphocytes during viral infection contribute to high NLRs and dismal prognoses. Intervention at the early stage of anti-MDA5 + DM, when elevated NLRs may first be detected, may prevent or delay the development of cytokine storms and tissue damage.

Plasma LDH levels have previously been reported to be increased in RPILD and associated with high titers of anti-MDA5 antibody. A recent study has suggested that LDH > 335/L was an independent risk factor for poor prognosis in anti-MDA5 + DM [3]. The current study found that serum LDH in patients with NLR > 4.86 was significantly higher than that in patients with NLR < 4.86 (Fig. 1a). This suggests that NLR measurements have a related function to those of LDH. However, LDH is released by many tissues, such as liver and kidney, and is greatly affected by CK levels. Similarly, CRP is a general reflection of inflammation that has been widely validated clinically with higher initial CRP levels significantly associated with both RPILD and poor outcome in anti-MDA5 positive patients[39]. Consistent with these findings, our study demonstrated that serum CRP was significantly higher in patients with NLR > 4.86 (Fig. 1b). Therefore, NLR may prove to be a more appropriate indicator of inflammatory state in anti-MDA5 + DM.

Previous studies have identified HRCT score as an independent risk factor for poor prognosis in anti-MDA5 + DM [5] but the current studies do not replicate those results. This inconsistency may have arisen due to selection of first admission HRCT images from patients who have been hospitalized and scanned on several occasions.

Some DM patients deteriorate rapidly, often within the time-scale of 1 month. Therefore, early HRCT scores may not reliably indicate abnormality and vigilance is required to ensure repeated scans on follow-up.

We acknowledge several limitations to the current study. All data were derived from patients presenting at a single center. We did not include ferritin in further analysis because nearly 50% of the ferritin values in our data set were missing, a deficiency that cannot be compensated by statistical methods. Moreover, NLR measured at initial presentation was included but not that after treatment, so that NLR changes could not be assessed. In addition, many factors, including treatment program and inflammatory severity, contribute to poor prognosis in anti-MDA5 + DM. Prognosis must be evaluated in combination with other indicators.

Conclusion

In conclusion, NLR less than 4.86 was found to be an independent predictor of longer survival for patients with MDA5 + DM. NLR may prove to be a marker with clinical utility due to its low cost, accessibility and reproducibility.

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due to ethical/legal/commercial reasons but are available from the corresponding author on reasonable request.

References

Uncategorized References

  1. DeWane ME, Waldman R, Lu J. Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol. 2020;82(2):267–81. https://doi.org/10.1016/j.jaad.2019.06.1309.

    Article  CAS  PubMed  Google Scholar 

  2. Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features pathogenesis and emerging therapies. Front Immunol. 2021;12:773352. https://doi.org/10.3389/fimmu.2021.773352.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Yoshifuji H. Biomarkers and autoantibodies of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circ Respir Pulm Med. 2015;9(Suppl 1):141–6. https://doi.org/10.4137/CCRPM.S36748.

    Article  PubMed  Google Scholar 

  4. Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49(9):1713–9. https://doi.org/10.1093/rheumatology/keq149.

    Article  CAS  PubMed  Google Scholar 

  5. Fujiki Y, Kotani T, Isoda K, Ishida T, Shoda T, Yoshida S, Takeuchi T, Makino S. Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Mod Rheumatol. 2018;28(1):133–40. https://doi.org/10.1080/14397595.2017.1318468.

    Article  CAS  PubMed  Google Scholar 

  6. Mammen AL, Allenbach Y, Stenzel W, Benveniste O. Group EtWS: 239th ENMC international workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018. Neuromuscul Disord. 2020;30(1):70–92. https://doi.org/10.1016/j.nmd.2019.10.005.

    Article  PubMed  Google Scholar 

  7. Ye S, Chen XX, Lu XY, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007;26(10):1647–54. https://doi.org/10.1007/s10067-007-0562-9.

    Article  PubMed  Google Scholar 

  8. Akira M. CT findings during phase of accelerated deterioration in patients with idolathic pulmonary fibrosis; 1997.

  9. Ichikado K, Suga M, Muller NL, et al. Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and nonsurvivors. Am J Respir Crit Care Med. 2002;165(11):1551–6. https://doi.org/10.1164/rccm.2106157.

    Article  PubMed  Google Scholar 

  10. Wu W, Guo L, Fu Y, Wang K, Zhang D, Xu W, Chen Z, Ye S. Interstitial lung disease in Anti-MDA5 positive dermatomyositis. Clin Rev Allergy Immunol. 2021;60(2):293–304. https://doi.org/10.1007/s12016-020-08822-5.

    Article  CAS  PubMed  Google Scholar 

  11. Erre GL, Paliogiannis P, Castagna F, Mangoni AA, Carru C, Passiu G, Zinellu A. Meta-analysis of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in rheumatoid arthritis. Eur J Clin Investig. 2019. https://doi.org/10.1111/eci.13037.

    Article  Google Scholar 

  12. Alan S, Tuna S, Turkoglu EB. The relation of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume with the presence and severity of Behcet’s syndrome. Kaohsiung J Med Sci. 2015;31(12):626–31. https://doi.org/10.1016/j.kjms.2015.10.010.

    Article  PubMed  Google Scholar 

  13. Avcı A, Avcı D, Erden F, Ragip E, Cetinkaya A, Ozyurt K, Atasoy M. Can we use the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume values for the diagnosis of anterior uveitis in patients with Behcet&rsquo;s disease? Ther Clin Risk Manag. 2017;13:881–6. https://doi.org/10.2147/tcrm.S135260.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kim DS, Shin D, Lee MS, Kim HJ, Kim DY, Kim SM, Lee M-G. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol. 2016;43(3):305–10. https://doi.org/10.1111/1346-8138.13061.

    Article  PubMed  Google Scholar 

  15. Wu Y, Chen Y, Yang X, Chen L, Yang Y. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with disease activity in patients with systemic lupus erythematosus. Int Immunopharmacol. 2016;36:94–9. https://doi.org/10.1016/j.intimp.2016.04.006.

    Article  CAS  PubMed  Google Scholar 

  16. Li W, Liu S, Chen C, Han Y. Neutrophil-to-lymphocyte ratios and platelet-to-lymphocyte ratios in juvenile systemic lupus erythematosus: correlation with disease manifestations. Ann Palliat Med. 2021;10(9):9406–14.

    Article  Google Scholar 

  17. Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology. 2012;51(9):1563–70. https://doi.org/10.1093/rheumatology/kes102.

    Article  CAS  PubMed  Google Scholar 

  18. Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T, Arima M, Maezawa R. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology. 2018;57(12):2114–9. https://doi.org/10.1093/rheumatology/key188.

    Article  CAS  PubMed  Google Scholar 

  19. Ye Y, Fu Q, Wang R, Guo Q, Bao C. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease. J Clin Lab Anal. 2019;33(8):e22978. https://doi.org/10.1002/jcla.22978.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wang K, Zhao J, Chen Z, et al. CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease. Rheumatology. 2019;58(3):511–21. https://doi.org/10.1093/rheumatology/key341.

    Article  CAS  PubMed  Google Scholar 

  21. Ono N, Kai K, Maruyama A, Sakai M, Sadanaga Y, Koarada S, Inoue T, Tada Y. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. Rheumatology. 2019;58(5):786–91. https://doi.org/10.1093/rheumatology/key386.

    Article  CAS  PubMed  Google Scholar 

  22. He C, Chen J, Luo X, Yan B. Evaluation of biomarkers related to endothelial dysfunction: proof of vasculopathy in anti-melanoma differentiation-associated gene 5 dermatomyositis. Clin Exp Rheumatol. 2021;39(1):151–7.

    Article  Google Scholar 

  23. Olivé M, Unzeta M, Moreno D, Ferrer I. Overexpression of semicarbazide-sensitive amine oxidase in human myopathies. Muscle Nerve. 2004;29(2):261–6. https://doi.org/10.1002/mus.10550.

    Article  CAS  PubMed  Google Scholar 

  24. Bae SS, Lee YY, Shahbazian A, et al. High- density lipoprotein function is abnormal in idiopathic inflammatory myopathies. Rheumatology. 2020;59(11):3515–25. https://doi.org/10.1093/rheumatology/keaa273.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Mititelu RR, Padureanu R, Bacanoiu M, Padureanu V, Docea AO, Calina D, Barbulescu AL, Buga AM. Inflammatory and oxidative stress markers-mirror tools in rheumatoid arthritis. Biomedicines. 2020. https://doi.org/10.3390/biomedicines8050125.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Padureanu R, Albu CV, Mititelu RR, et al. Oxidative stress and inflammation interdependence in multiple sclerosis. J Clin Med. 2019. https://doi.org/10.3390/jcm8111815.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–81. https://doi.org/10.1016/j.lungcan.2017.07.024.

    Article  PubMed  Google Scholar 

  28. Fang T, Wang Y, Yin X, et al. Diagnostic sensitivity of NLR and PLR in early diagnosis of gastric cancer. J Immunol Res. 2020;2020:9146042. https://doi.org/10.1155/2020/9146042.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Valero C, Lee M, Hoen D, et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021;12(1):729. https://doi.org/10.1038/s41467-021-20935-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Zhang H, Ding L, Shi X, et al. Imperatorin alleviated NLR family pyrin domain-containing 3 inflammasome cascade-induced synovial fibrosis and synovitis in rats with knee osteoarthritis. Bioengineered. 2021;12(2):12954–64. https://doi.org/10.1080/21655979.2021.2012949.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Cai C, Zhang R, Xu X, Li G, Gou H. Diagnostic values of NLR and miR-141 in patients with osteoarthritis and their association with severity of knee osteoarthritis. Exp Ther Med. 2021;21(1):74. https://doi.org/10.3892/etm.2020.9506.

    Article  CAS  PubMed  Google Scholar 

  32. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102(6):653–7. https://doi.org/10.1016/j.amjcard.2008.05.006.

    Article  PubMed  Google Scholar 

  33. Park JJ, Jang HJ, Oh IY, et al. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2013;111(5):636–42. https://doi.org/10.1016/j.amjcard.2012.11.012.

    Article  PubMed  Google Scholar 

  34. Li Y, Li Y, Wu J, et al. Predictors of poor outcome of anti-MDA5-associated rapidly progressive interstitial lung disease in a chinese cohort with dermatomyositis. J Immunol Res. 2020;2020:2024869. https://doi.org/10.1155/2020/2024869.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, Sun L. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res. 2013;65(8):1316–24. https://doi.org/10.1002/acr.21985.

    Article  CAS  Google Scholar 

  36. So J, So H, Wong VT-L, et al. Predictors of rapidly progressive-interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis. Rheumatology. 2022. https://doi.org/10.1093/rheumatology/keac094.

    Article  PubMed  Google Scholar 

  37. Nishina N, Sato S, Masui K, Gono T, Kuwana M. Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD Open. 2020. https://doi.org/10.1136/rmdopen-2020-001202.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Toquet S, Granger B, Uzunhan Y, Mariampillai K, Nunes H, Benveniste O, Allenbach Y. The seasonality of Dermatomyositis associated with anti-MDA5 antibody: An argument for a respiratory viral trigger. Autoimmun Rev. 2021;20(4):102788. https://doi.org/10.1016/j.autrev.2021.102788.

    Article  CAS  PubMed  Google Scholar 

  39. Yang Q, Li T, Zhang X, Lyu K, Wu S, Chen Y, Liu S, Yu Z. Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients. Orphanet J Rare Dis. 2021;16(1):58. https://doi.org/10.1186/s13023-021-01705-8.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to express their gratitude to EditSprings (https://www.editsprings.cn ) for the expert linguistic services provided.

Funding

This study is supported by the Clinical Research Incubation Project and 1.3.5 Project for Disciplines of Excellence of West China Hospital, Sichuan University (2019HXFH038 and ZYJC18021) and Sichuan Science and Technology Program (2021JDRC0045, 2021YFS0164, and 2021JDRC0169).

Author information

Authors and Affiliations

  1. Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People’s Republic of China

    Tao Liu & Qibing Xie

  2. West China School of Public Health/West China Fourth Hospital, Sichuan University, Chengdu, 610041, Sichuan, People’s Republic of China

    Wen Li, Zehao Zhang, Ting Jiang, Yu Fei & Jing Huang

Authors
  1. Tao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zehao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ting Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu Fei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jing Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qibing Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Concept and design-Tao Liu, Qibing Xie, acquisition of subjects and/or data- Wen Li, Zehao Zhang, Ting Jiang, Yu Fei, Jing Huang, analysis and interpretation of data- Tao Liu, and the preparation of manuscript- Tao Liu. All the authors read and approve the final manuscript.

Corresponding author

Correspondence to Qibing Xie.

Ethics declarations

Ethics approval and consent to participants

The study complied with the Declaration of Helsinki and is approved by the ethics committee of West China Hospital (No. 246 in 2019). All methods were carried out in accordance with relevant guidelines and regulations. There is no informed consent from participants because of the retrospective nature of the study. The ethics committee of West China Hospital approved an informed consent waiver.

Consent for publication

Not applicable. The manuscript does not include any information or image that could lead to identification of a study participant.

Competing interests

All the authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1. Figure S1

: Receiver operator characteristic curves for predicting non-survival between NLR ≤ 4.86 and NLR > 4.86 in anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody-positive dermatomyositis.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, T., Li, W., Zhang, Z. et al. Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis. BMC Pulm Med 22, 316 (2022). https://doi.org/10.1186/s12890-022-02106-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12890-022-02106-8

Keywords

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us